Co-administration of pirfenidone with other antifibrotic agents such as nintedanib has not been widely studied. Combining these therapies should only be considered in a specialist centre where patients can be closely monitored for additive side effects, particularly liver toxicity.
Smoking induces the CYP1A2 enzyme, which can lower pirfenidone plasma concentrations and potentially reduce its effectiveness. Smoking cessation is strongly recommended for anyone receiving Esbriet.
Pirfenidone is not listed as a prohibited substance by the World Anti-Doping Agency (WADA). However, athletes should disclose all medications to their anti-doping organization, as formulation excipients or metabolites could occasionally trigger alerts.
Common antihistamines (e.g., cetirizine, loratadine) do not significantly affect pirfenidone metabolism and are generally considered safe. Nonetheless, patients should inform their healthcare provider of all OTC medicines they use.
Yes, but keep the medication in its original labelled container, carry a copy of the prescription, and be aware of any import restrictions in the destination country. The UK’s NHS travel advice recommends a maximum of 30 days’ supply without additional documentation.
Immediately discontinue sun exposure, apply a soothing, fragrance-free moisturizer, and seek medical evaluation. Severe or widespread photosensitivity may require temporary cessation of Esbriet.
Pirfenidone absorption is not significantly affected by dietary protein content. The important factor is taking the tablets with food to minimise gastrointestinal upset.
Unused Esbriet tablets should be returned to a pharmacy collection point or disposed of according to the NHS “Dispose of medicines safely” programme. Do not flush tablets down the toilet.
As of the current regulatory landscape, pirfenidone is marketed primarily under the brand name Esbriet in the UK. Generic equivalents may become available after patent expiry, but patients should only use products approved by the MHRA.
Esbriet is a brand-name medication that contains pirfenidone as its active ingredient. It is supplied as oral pills in strengths of 200 mg and 400 mg. In the United Kingdom, Esbriet is a prescription-only medicine (Rx) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). The drug is primarily prescribed for the treatment of idiopathic pulmonary fibrosis (IPF), a chronic, progressive lung disease that leads to scarring (fibrosis) of lung tissue and causes breathing difficulties.
Pirfenidone belongs to a class of agents that modify the body’s response to injury within lung tissue. Its exact mechanism is not fully understood, but research shows several key actions:
These combined actions slow the progression of scarring, helping to preserve lung function and delay worsening of breathing problems in IPF.
Esbriet is not approved for asthma, chronic obstructive pulmonary disease (COPD), or other respiratory conditions. Use for those indications would be considered off-label and should only occur under specialist supervision.
Pirfenidone dosing follows a titration protocol to improve tolerability:
Doses should be taken at evenly spaced intervals (approximately every 8 hours) to maintain steady blood levels.
If a dose is missed and the next scheduled dose is more than 4 hours away, skip the missed dose and resume the regular schedule. Do not double-dose to make up for a forgotten tablet.
Symptoms may include nausea, vomiting, abdominal pain, and severe photosensitivity. Seek emergency medical care immediately. Activated charcoal may be considered if presentation is early. No specific antidote exists; treatment is supportive.
Abrupt cessation is generally safe, but patients should discuss any plan to stop therapy with their healthcare provider, especially if they have been on the maintenance dose for several months. No tapering is required, but monitoring for disease progression after discontinuation is essential.
This article provides educational information about Esbriet (pirfenidone) and is not a substitute for professional medical advice. Treatment decisions, including the use of any medication for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
